DrugPatentWatch Database Preview» See Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,132,202
|Title:||Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance|
|Abstract:||Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as reduced skin sagging, increased skin thickness, reduced wrinkles, increased skin thickness and collagen content, increased skin tone and elasticity, increased skin hydration, and improved skin texture and color.|
|Inventor(s):||Tabor; Aaron T. (Winston-Salem, NC)|
|Patent Claims:||1. A method for the cosmetic genetic modification of skin cells having a cosmetic function in a subject comprising: topically administering a NTX-keratinocyte growth
factor-1 plasmid to the skin cells of the subject, wherein the plasmid comprises an isolated polynucleotide encoding a keratinocyte growth factor-1 polypeptide, such that the keratinocyte growth factor-1 polypeptide is expressed in the skin cells having
cosmetic function to enhance or maintain a biochemical or physiological process or both that has a positive effect on cosmetic appearance.
2. The method of claim 1, wherein the polynucleotide comprises at least one sequence selected from the group consisting of: (i) nucleotides 446 to 1030 of SEQ ID NO: 24; (ii) a sequence that is at least 90% identical to nucleotides 446 to 1030 of SEQ ID NO: 24; and (iii) a polynucleotide that encodes a protein having the sequence of SEQ ID NO: 23.
3. The method of claim 1, wherein the polynucleotide is maintained as a extrachromosomal plasmid.
4. The method of claim 1, wherein the polynucleotide is operably linked to a constitutive or an inducible promoter.
5. The method of claim 4, wherein the promoter is not ubiquitously expressed, but is expressed in the cells having cosmetic function.
6. The method of claim 1, wherein the polynucleotide is operably linked to an enhancer.
7. The method of claim 1, wherein the polynucleotide is operably linked to at least one of a functional poly A sequence, an intron, a cleavage sequence, a stop sequence, and a cap site.
8. The method of claim 1, wherein the polynucleotide is introduced as naked DNA into the cells having a cosmetic function.
9. The method of claim 1, wherein the polynucleotide is introduced into the cells having a cosmetic function via at least one of liposomes, nanoparticles, an emulsion, a thixogel, and an organoleptic gel.
10. The method of claim 1, wherein the polynucleotide is introduced into the cells having a cosmetic function via a water-in-oil emulsion or an oil-in-water emulsion.
11. The method of claim 1, wherein the polynucleotide is introduced into the cells having a cosmetic function via at least one of particle mediated transfer, voltage driven transfer, radio frequency ablation-mediated transfer, ultrasound, and microneedles.
12. The method of claim 1, wherein the plasmid comprising the isolated polynucleotide is topically administered in a composition comprising TE buffer, glycerin, and hydroxypropyl methylcellulose.
13. The method of claim 12, wherein the composition further comprises propylene glycol.
Summary for Patent: Start Trial
|PCT Filed||July 15, 2010||PCT Application Number:||PCT/US2010/042051|
|PCT Publication Date:||January 20, 2011||PCT Publication Number:||WO2011/008904|
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||Start Trial||2029-07-17||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||Start Trial||2029-07-17||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||Start Trial||2029-07-17||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Estimated Expiration|
|World Intellectual Property Organization (WIPO)||2011008904||Start Trial|
|United States of America||2012115938||Start Trial|
|European Patent Office||2454368||Start Trial|
|>Country||>Patent Number||>Estimated Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.